Literature DB >> 18171244

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.

Brad Spellberg1, Robert Guidos, David Gilbert, John Bradley, Helen W Boucher, W Michael Scheld, John G Bartlett, John Edwards.   

Abstract

The ongoing explosion of antibiotic-resistant infections continues to plague global and US health care. Meanwhile, an equally alarming decline has occurred in the research and development of new antibiotics to deal with the threat. In response to this microbial "perfect storm," in 2001, the federal Interagency Task Force on Antimicrobial Resistance released the "Action Plan to Combat Antimicrobial Resistance; Part 1: Domestic" to strengthen the response in the United States. The Infectious Diseases Society of America (IDSA) followed in 2004 with its own report, "Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, A Public Health Crisis Brews," which proposed incentives to reinvigorate pharmaceutical investment in antibiotic research and development. The IDSA's subsequent lobbying efforts led to the introduction of promising legislation in the 109 th US Congress (January 2005-December 2006). Unfortunately, the legislation was not enacted. During the 110 th Congress, the IDSA has continued to work with congressional leaders on promising legislation to address antibiotic-resistant infection. Nevertheless, despite intensive public relations and lobbying efforts, it remains unclear whether sufficiently robust legislation will be enacted. In the meantime, microbes continue to become more resistant, the antibiotic pipeline continues to diminish, and the majority of the public remains unaware of this critical situation. The result of insufficient federal funding; insufficient surveillance, prevention, and control; insufficient research and development activities; misguided regulation of antibiotics in agriculture and, in particular, for food animals; and insufficient overall coordination of US (and international) efforts could mean a literal return to the preantibiotic era for many types of infections. If we are to address the antimicrobial resistance crisis, a concerted, grassroots effort led by the medical community will be required.

Entities:  

Mesh:

Year:  2008        PMID: 18171244     DOI: 10.1086/524891

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  464 in total

1.  Occurrence of Antimicrobial-Resistant Escherichia coli and Salmonella enterica in the Beef Cattle Production and Processing Continuum.

Authors:  John W Schmidt; Getahun E Agga; Joseph M Bosilevac; Dayna M Brichta-Harhay; Steven D Shackelford; Rong Wang; Tommy L Wheeler; Terrance M Arthur
Journal:  Appl Environ Microbiol       Date:  2014-11-14       Impact factor: 4.792

2.  In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection.

Authors:  C Silvestri; O Cirioni; D Arzeni; R Ghiselli; O Simonetti; F Orlando; G Ganzetti; S Staffolani; L Brescini; M Provinciali; A Offidani; M Guerrieri; A Giacometti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-11       Impact factor: 3.267

Review 3.  A review of antibiotic use in food animals: perspective, policy, and potential.

Authors:  Timothy F Landers; Bevin Cohen; Thomas E Wittum; Elaine L Larson
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

4.  First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective.

Authors:  György-Miklós Buzás
Journal:  World J Gastroenterol       Date:  2010-08-21       Impact factor: 5.742

5.  Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.

Authors:  Yigong Ge; M J Whitehouse; Ian Friedland; George H Talbot
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

6.  Staphylococcus aureus virulence attenuation and immune clearance mediated by a phage lysin-derived protein.

Authors:  Hang Yang; Jingjing Xu; Wuyou Li; Shujuan Wang; Junhua Li; Junping Yu; Yuhong Li; Hongping Wei
Journal:  EMBO J       Date:  2018-07-23       Impact factor: 11.598

7.  How Can We Optimize Antibiotic Use in the PICU?

Authors:  Kathleen Chiotos; Jeffrey S Gerber; Adam S Himebauch
Journal:  Pediatr Crit Care Med       Date:  2017-09       Impact factor: 3.624

8.  Exploring N-acylhydrazone derivatives against clinical resistant bacterial strains.

Authors:  Andressa C Lannes; Bruno Leal; Juliana S Novais; Viviane Lione; Georgia C T S Monteiro; André L Lourenço; Plínio C Sathler; Alessandro K Jordão; Carlos R Rodrigues; Lúcio M Cabral; Anna Claudia Cunha; Vinicius Campos; Vítor F Ferreira; Maria Cecília B V de Souza; Dilvani O Santos; Helena C Castro
Journal:  Curr Microbiol       Date:  2014-05-08       Impact factor: 2.188

9.  The identification of inhibitory compounds of Rickettsia prowazekii methionine aminopeptidase for antibacterial applications.

Authors:  Travis R Helgren; Elif S Seven; Congling Chen; Thomas E Edwards; Bart L Staker; Jan Abendroth; Peter J Myler; James R Horn; Timothy J Hagen
Journal:  Bioorg Med Chem Lett       Date:  2018-03-15       Impact factor: 2.823

10.  Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method.

Authors:  Thea Brennan-Krohn; James E Kirby
Journal:  J Vis Exp       Date:  2019-04-18       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.